(R) and (S) isomers of substituted 2-(2,6-dioxopiperidin-3-yl) phthalimides and 1-oxoisoindolines and methods of using the same
Substituted 2-(2,6-dioxopiperidin-3-yl) phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl) isoindolines reduce the levels of TNFα in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline and 1,3-dioxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-aminoisoindoline.
1. A pharmaceutical composition comprising a therapeutically effective amount of the (S)-isomer of a compound of the formula:
or an acid addition salt of said isomer, wherein the (S) isomer is substantially free of its (R) isomer, in combination with a pharmaceutically and physiologically suitable carrier.
2. A single unit dosage form of the pharmaceutical composition according to claim 1 , wherein the dosage form is a powder, tablet, capsule or an injectable composition.
3. A pharmaceutical composition comprising a therapeutically effective amount of the (R)-isomer of a compound of the formula:
or an acid addition salt of said isomer, wherein the (R) isomer is substantially free of its (S) isomer, in combination with a pharmaceutically and physiologically suitable carrier.
4. A single unit dosage form of the pharmaceutical composition according to claim 3 , wherein the dosage form is as a powder, tablet, capsule or an injectable composition.
5. The pharmaceutical composition of claim 1 , wherein the (S) isomer has an optical purity of greater than 95%.
6. The pharmaceutical composition of claim 3 , wherein the (R) isomer has an optical purity of greater than 95%.
7. The pharmaceutical composition of claim 1 , wherein the composition is suitable for parenteral administration.
8. The pharmaceutical composition of claim 7 , which is a composition suitable for intravenous administration.
9. The pharmaceutical composition of claim 7 , which comprises a sterile injectable solution.
10. The pharmaceutical composition of claim 3 , wherein the composition is suitable for parenteral administration.
11. The pharmaceutical composition of claim 10 , which is a composition suitable for intravenous administration.
12. The pharmaceutical composition of claim 10 , which comprises a sterile injectable solution.